Human malignant melanoma. A genetic disease?
- 15 March 1995
- Vol. 75 (6) , 1228-1237
- https://doi.org/10.1002/1097-0142(19950315)75:6<1228::aid-cncr2820750604>3.0.co;2-t
Abstract
Background. Human hereditary malignant melanoma, comprising 5% of all cases of malignant melanoma, occurs in association with other malignancies, predominantly in families with dysplastic nevus syndrome. Additionally, higher incidences of malignant melanoma have been reported in individuals with genetic disorders such as ataxia telangiectasia and xeroderma pigmentosum. The results and observations as reported in the literature on the involvement of oncogenes and chromosomal aberrations in the development of malignant melanoma are reviewed and compared with the authors' own experimental and clinical experience. Results. Numerous chromosomal regions, as on chromosomes 1 and 9, were altered. The long arm of chromosome 6 was affected in 60% of melanomas. Introduction of a normal copy of chromosome 6 resulted in loss of tumorigenicity in vitro. True melanoma genes were evident in two animal models: the Sinclair swine and the teleost fish Xiphophorus. In the Xiphophorus system, the crossing-conditioned elimination of a tumor suppressor gene led to the uncontrolled activity of a dominantly acting oncogene in certain hybrids. The causative oncogene, Xmrk, encodes a receptor tyrosine kinase closely related to human epidermal growth factor receptor (EGFR). Among the numerous studied human oncogenes, mutations in the extensively investigated ras family are the result rather than the cause of malignant transformation. High expression of nuclear oncogenes simply may be a common feature of rapidly dividing cells. The receptor tyrosine kinase EGFR may be involved in late stage melanoma; the human exon with homology to Xmrk shows elevated transcription levels in 80% of human melanoma metastases. Deletions of the tumor suppressor gene MTS 1 may be important for melanoma formation, whereas deletions of p53 appear to be of minor relevance. Conclusion. Scientific progress in treating and diagnosing malignant melanoma will largely depend on experimental approaches to define relevant genetic changes by functional analysis rather than descriptive phenomenology and correlative observations. Cancer 1995;75:1228-37.Keywords
This publication has 78 references indexed in Scilit:
- Nonmelanoma Cancers of the SkinNew England Journal of Medicine, 1992
- PREVALENCE OF DYSPLASTIC NEVI IN HEALTHY YOUNG MENInternational Journal of Dermatology, 1992
- Regional distribution of common and dysplastic naevi in relation to melanoma site and sun exposure. A case-control studyMelanoma Research, 1992
- Novel putative receptor tyrosine kinase encoded by the melanoma-inducing Tu locus in XiphophorusNature, 1989
- Mapping the Gene for Hereditary Cutaneous Malignant Melanoma–Dysplastic Nevus to Chromosome LpNew England Journal of Medicine, 1989
- Loss of Heterozygosity at Polymorphic Chromosomal Loci in Patients with Malignant MelanomaJournal of Investigative Dermatology, 1989
- Possible involvement of the chromosome region 10q24→q26 in early stages of melanocytic neoplasiaCancer Genetics and Cytogenetics, 1988
- Familial cutaneous malignant melanoma: autosomal dominant trait possibly linked to the Rh locus.Proceedings of the National Academy of Sciences, 1983
- Chromosome 6q involvement in human malignant melanomaCancer Genetics and Cytogenetics, 1983
- Nonepidermal Origin of Malignant Melanoma Associated with a Giant Congenital Nevocellular NevusPlastic and Reconstructive Surgery, 1981